Sabra Health Care REIT, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Sabra Health Care REIT, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $774.63M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $703.24M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $647.51M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $624.81M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $569.55M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $598.57M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $661.74M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $623.41M | Aug 6, 2021 |
| FY2019 | Dec 31, 2017 | $408.28M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $260.53M | Feb 25, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $356.88M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $284.58M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $236.15M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $186.67M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $155.51M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $156.05M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $128.06M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $70.14M | Aug 6, 2021 |
| FY2019 | Dec 31, 2017 | $26.43M | Feb 24, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $155.61M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $126.71M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $13.76M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($77.61M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | ($113.26M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $138.42M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $69.00M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $279.08M | Aug 6, 2021 |
| FY2019 | Dec 31, 2017 | $158.38M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $70.28M | Feb 25, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $348.61M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $310.54M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $300.57M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $315.73M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $356.39M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $354.85M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $372.48M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $360.59M | Aug 6, 2021 |
| FY2019 | Dec 31, 2017 | $135.79M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $175.93M | Feb 25, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.49B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $5.30B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $5.39B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $5.75B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $5.97B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $5.99B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $6.07B | Aug 6, 2021 |
| FY2019 | Dec 31, 2018 | $6.67B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $7.03B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $2.27B | Feb 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.67B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.56B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $2.58B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $2.69B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $2.59B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $2.58B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $2.58B | Aug 6, 2021 |
| FY2019 | Dec 31, 2018 | $3.41B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $3.60B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $1.25B | Feb 21, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.82B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.74B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $2.80B | Feb 19, 2025 |
| FY2024 | Dec 31, 2022 | $3.06B | Feb 19, 2025 |
| FY2024 | Dec 31, 2021 | $3.38B | Feb 19, 2025 |
| FY2023 | Dec 31, 2020 | $3.41B | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | $3.49B | Feb 21, 2023 |
| FY2019 | Dec 31, 2018 | $3.25B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $3.43B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $1.02B | Feb 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.54M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $60.47M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $41.29M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $49.31M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $112.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $59.08M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $39.10M | Aug 6, 2021 |
| FY2019 | Dec 31, 2018 | $50.23M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $518.63M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $25.66M | Feb 21, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.53B | Feb 12, 2026 |
| FY2024 | Dec 31, 2024 | $2.42B | Feb 19, 2025 |
| FY2023 | Dec 31, 2023 | $2.41B | Feb 27, 2024 |
| FY2022 | Dec 31, 2022 | $2.51B | Feb 21, 2023 |
| FY2021 | Dec 31, 2021 | $2.39B | Feb 22, 2022 |
| FY2020 | Dec 31, 2020 | $2.37B | Aug 6, 2021 |
| FY2019 | Dec 31, 2019 | $2.40B | Feb 24, 2020 |
| FY2018 | Dec 31, 2018 | $3.23B | Feb 25, 2019 |
| FY2017 | Dec 31, 2017 | $3.39B | Feb 21, 2018 |
| FY2016 | Dec 31, 2016 | $1.21B | Feb 22, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | 1 | Aug 6, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 25, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | 1 | Aug 6, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 25, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 251.70M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 237.59M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | 231.27M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 231.01M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 230.40M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | 210.56M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | 205.21M | Aug 6, 2021 |
| FY2019 | Dec 31, 2018 | 178.31M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | 178.26M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | 65.29M | Feb 21, 2018 |